

Claims

27

- AD
1. A method of treatment of a disease or a condition requiring the administration of an antioxidant, which comprises administering to a patient an effective amount of a secoisolariciresinol diglucoside (SDG) metabolite selected from the group consisting of secoisolariciresinol (SECO) in a substantially pure form, enterodiol (ED) in a substantially pure form, and enterolactone (EL) in a substantially pure form.
 2. A method according to claim 1 wherein said disease is hypercholesterolemic atherosclerosis.
 3. A method according to claim 1 wherein said disease is diabetes type I or type II.
 4. A method according to claim 1 wherein said condition is ischemic heart disease.
 5. A method according to claim 1 wherein said condition is volume or pressure overload heart failure.
 6. A method according to claim 1 wherein said condition is the prevention of myocardial injury during open heart surgery.
 7. A method according to claim 1 wherein said condition is the prevention of restenosis following percutaneous transluminal coronary angioplasty (PTCA).
 8. A method according to claim 1 wherein said condition is hemorrhagic or endotoxic shock.
 9. A method according to claim 1 wherein said condition is ageing.
 10. A method according to claim 1 wherein said disease is inflammatory bowel disease (Crohn's disease, ulcerative colitis).
 11. A method according to claim 1 wherein said disease is Parkinson's disease.
 12. A method according to claim 1 wherein said disease is rheumatoid arthritis.
 13. A method according to claim 1 wherein said disease is stroke.
 14. A method according to claim 1 wherein secoisolariciresinol diglucoside (SDG) is obtained from flaxseed, and said metabolite is obtained from SDG.

ΔC_1